4//SEC Filing
Hata Yujiro S 4
Accession 0001610717-24-000239
CIK 0001676725other
Filed
May 15, 8:00 PM ET
Accepted
May 16, 5:51 PM ET
Size
27.2 KB
Accession
0001610717-24-000239
Insider Transaction Report
Form 4
Hata Yujiro S
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Stock
2024-05-14$4.31/sh+56,711$244,424→ 734,598 total - Sale
Common Stock
2024-05-14$41.60/sh−54,408$2,263,433→ 680,190 total - Sale
Common Stock
2024-05-14$41.84/sh−2,303$96,348→ 677,887 total - Exercise/Conversion
Stock Option (right to buy)
2024-05-15−83,856→ 83,887 totalExercise: $4.31Exp: 2028-02-26→ Common Stock (83,856 underlying) - Exercise/Conversion
Common Stock
2024-05-15$4.31/sh+83,856$361,419→ 761,743 total - Sale
Common Stock
2024-05-15$42.57/sh−53,592$2,281,631→ 708,151 total - Sale
Common Stock
2024-05-15$43.48/sh−29,761$1,293,934→ 678,390 total - Sale
Common Stock
2024-05-15$44.12/sh−503$22,191→ 677,887 total - Exercise/Conversion
Common Stock
2024-05-16$4.31/sh+34,433$148,406→ 712,320 total - Sale
Common Stock
2024-05-16$41.73/sh−30,084$1,255,505→ 682,236 total - Sale
Common Stock
2024-05-16$42.37/sh−4,349$184,250→ 677,887 total - Exercise/Conversion
Stock Option (right to buy)
2024-05-14−56,711→ 167,743 totalExercise: $4.31Exp: 2028-02-26→ Common Stock (56,711 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-05-16−34,433→ 49,454 totalExercise: $4.31Exp: 2028-02-26→ Common Stock (34,433 underlying)
Footnotes (9)
- [F1]The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 22, 2023.
- [F2]This transaction was executed in multiple trades in prices ranging from $40.815 to $41.80, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]This transaction was executed in multiple trades in prices ranging from $41.81 to $41.945, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F4]This transaction was executed in multiple trades in prices ranging from $42.08 to $43.07, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F5]This transaction was executed in multiple trades in prices ranging from $43.09 to $43.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F6]This transaction was executed in multiple trades in prices ranging from $44.10 to $44.14, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F7]This transaction was executed in multiple trades in prices ranging from $41.2651 to $42.25, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F8]This transaction was executed in multiple trades in prices ranging from $42.26 to $42.595, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F9]The shares subject to the option are fully vested and exercisable.
Documents
Issuer
IDEAYA Biosciences, Inc.
CIK 0001676725
Entity typeother
Related Parties
1- filerCIK 0001649119
Filing Metadata
- Form type
- 4
- Filed
- May 15, 8:00 PM ET
- Accepted
- May 16, 5:51 PM ET
- Size
- 27.2 KB